Dr. Ian Flinn, chief scientific officer at Tennessee Oncology and One Oncology in Nashville, Tennessee, explains Lunsumio ...

Opportunities in the Global Refractory Follicular Lymphoma Diagnostics Market include the growing need for MRD monitoring and liquid biopsies, driven by the rise in hematologic malignancies. The surge ...

Dr. Ian Flinn explains in an interview with CURE how Lunsumio VELO (mosunetuzumab) works and its impact on patients with ...

New three-year follow-up results from the TRANSCEND FL trial show that patients with relapsed or refractory follicular lymphoma can achieve durable, multi-year remission with chimeric antigen receptor ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adults with relapsed or refractory ...

In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

Gazyva is a prescription injection medicine used for people with certain cancers, such as chronic lymphocytic leukemia (CLL) and certain types of follicular lymphoma. It is a type of medicine known as ...

(a) The smear is composed of blood only (smear, Diff-Quik stain). (b) The smear shows foamy macrophages and degenerated cyst fluid, with no follicular cells (smear, Diff-Quik stain). (c) Scant ...